|
Dr. Leopold has more than 28 years of research and management experience in the field of cancer research and drug development. Dr. Leopold has extensive professional experience in cancer drug discovery and evaluation, target validation, clinical development of anticancer agents, contract research, toxicology, and engineering. His personal research interests have focused on various technologies for in vivo evaluation of anticancer potential and the in vivo assessment of drug function at the molecular level. Prior to joining MIR, Dr. Leopold was Executive Director of Cancer Pharmacology and Therapeutic Area Site Leader for Oncology at Pfizer's Ann Arbor Laboratories. He was a co-founder of the Cancer Drug Discovery Program at Parke-Davis in 1982, assuming leadership of the program in 1989. During his tenure at Parke Davis/Pfizer, more than 18 novel agents spanning at least 10 mechanistic classes were discovered and developed to clinical trial. Upon completion of his Ph.D., Dr. Leopold joined the Chemotherapy Division of Southern Research Institute as a Research Oncologist where he also worked in the Toxicology Division as a Research Toxicologist. Dr. Leopold received his Ph.D. in Oncology from the McArdle Institute for Cancer Research at theUniversity of Wisconsin. He also holds an M.S. in Biochemistry and a B.S. in Chemical Engineering, both from the University of Illinois. | 